# Dr. Mohit Seth

> Nuclear Medicine & Theranostics physician (MBBS, DNB Nuclear Medicine), based in Delhi, India. Specialises in precision oncology: 177Lu-PSMA and PRRT (177Lu-DOTATATE) radionuclide therapy, I-131 therapy, and Ga-68 FAPI / PSMA PET/CT imaging. First author on a published Journal of Nuclear Medicine study of Ga-68 FAPI PET/CT for lung-cancer staging. Currently seeking an international fellowship in nuclear medicine and radionuclide therapy.

## About
- Name: Dr. Mohit Seth
- Specialty: Nuclear Medicine, Theranostics, Precision Oncology
- Training: DNB (Nuclear Medicine), National Board of Examinations, New Delhi (https://natboard.edu.in/) — trained at Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC), Delhi (https://www.rgcirc.org/), 2023–2026
- Location: Delhi, India
- Website: https://drmohitseth.com/
- Email: drmohitnm@gmail.com
- LinkedIn: https://www.linkedin.com/in/dr-mohit-seth-nuclear-medicine

## Credentials
- MBBS — RNT Medical College, Udaipur
- DNB (Nuclear Medicine) — National Board of Examinations in Medical Sciences, New Delhi (2023–2026)
- Certificate, Radiomolecular Precision Oncology, Level 1 — ICPO Academy for Theranostics (https://www.theranostics.academy/), 15 Sep 2026, 18 teaching hours; signed by Prof. Dr. Richard Baum and Prof. Dr. Vikas Prasad. Ref. 20260915-RPO-000528.
- Registered with the Delhi Medical Council (Reg. No. 111664)

## Clinical experience
- 177Lu-PSMA radioligand therapy (metastatic castration-resistant prostate cancer): 168 post-therapy cases
- 177Lu-DOTATATE / PRRT (neuroendocrine tumours): 92 cases
- I-131 therapy (differentiated thyroid cancer, thyrotoxicosis): 255 post-therapy scans
- I-131 mIBG, Y-90 radioembolisation; inpatient radionuclide therapy management
- Molecular imaging: 22,000+ PET-CT and 2,300+ SPECT-CT studies (18F-FDG, Ga-68 PSMA, Ga-68 DOTANOC, Ga-68 FAPI, F-18 DOPA)

## Research
- First author (published): Seth M, Choudhury P, Darlong L, Gupta M, Gambhir A, Pathak A. "Incremental role of Ga-68 FAPI PET/CT for staging lung cancer evaluated for surgery: a prospective comparative study with 18F-FDG PET/CT." Journal of Nuclear Medicine 2025;66(suppl 1):252179. https://jnm.snmjournals.org/content/66/supplement_1/252179
  Key finding: in 16 treatment-naive surgical candidates, Ga-68 FAPI PET/CT was more sensitive than 18F-FDG PET/CT for nodal staging of lung cancer (sensitivity 84.6% vs 61.5%; AUC 0.84 vs 0.72; specificity 75.6% for both). Presented orally at SNMMI 2025, New Orleans.
- Full peer-reviewed manuscript of the above study is under review.
- Multiple first-author case reports (PSMA / FDG PET/CT incidental findings) — submitted.
- Best Resident Award, Department of Nuclear Medicine, RGCIRC, 2025.

## Professional activity
- Oral and poster presentations at SNMMI 2025 & 2026 (https://www.snmmi.org/), ANMPICON 2025, AOCNMB 2025.
- Active member of the nuclear-medicine community in India and internationally.

## Contact
- Email: drmohitnm@gmail.com
- Phone: +91 94616 50992
- LinkedIn: https://www.linkedin.com/in/dr-mohit-seth-nuclear-medicine